Press Releases
Media Contact:
Lorie Calvo
425-608-3008
Northwest Biotherapeutics to Present at the 21st Annual Meeting of the International Society for Biological Therapy of Cancer
DCVax®-Brain Clinical Data Update
BOTHELL, WA– October 26, 2006 – Northwest Biotherapeutics (OTCBB: WBT.OB) announced today that Linda Liau M.D., Ph.D. and Robert Prins, Ph.D. of the Department of Neuro Surgery at University of California at Los Angeles (UCLA) will present an update on the clinical data from two Phase I DCVax®-Brain clinical trials, including ongoing long-term survival data, being carried out at UCLA under the direction of Dr. Liau, the principal investigator. The company continues to follow survivors (9 of 18 are still alive, 8 of which are cancer free) in these two trials with survival times in these patients ranging from 10 months to over 6 years. In addition, the company supports a booster program for these 9 patients. The presentation will take place Saturday, October 28th beginning at 9:00 AM Pacific Time during the annual meeting of the International Society for Biological Therapy of Cancer (iSBTc) held at the Hyatt Regency Century Plaza in Los Angeles.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell based vaccines, and therapeutic antibodies. The Company's three lead product candidates are: DCVax®-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent non-metastatic prostate cancer, which is entering a Phase III clinical trial; DCVax®-Brain, a personalized dendritic cell vaccine for treatment of newly diagnosed Glioblastoma multiforme, which is entering a large Phase II clinical trial; and CXCR4 a therapeutic monoclonal antibody for treatment of solid tumors, that is in late preclinical development.
|
